Modelling NAFLD disease burden in four Asian regions—2019‐2030

Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia‐Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations.

[1]  J. Bongaarts,et al.  United Nations Department of Economic and Social Affairs, Population Division World Family Planning 2020: Highlights, United Nations Publications, 2020. 46 p. , 2020 .

[2]  B. Goh,et al.  Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center. , 2018, Transplantation proceedings.

[3]  S. Wild,et al.  Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study , 2018, Gut.

[4]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[5]  Y. Cho,et al.  Recent research trends and updates on nonalcoholic fatty liver disease , 2018, Clinical and molecular hepatology.

[6]  Y. Huang,et al.  Call for data contribution to the IDF Diabetes Atlas 9th Edition 2019. , 2018, Diabetes research and clinical practice.

[7]  Z. Younossi.  The epidemiology of nonalcoholic steatohepatitis , 2018, Clinical liver disease.

[8]  Myeong Jun Song,et al.  Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the GO ASIA initiative , 2018, Alimentary pharmacology & therapeutics.

[9]  V. Wong,et al.  The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups , 2018, Journal of gastroenterology and hepatology.

[10]  V. Wong,et al.  Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment , 2018, Journal of gastroenterology and hepatology.

[11]  Gretchen A. Stevens,et al.  Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults , 2017, Lancet.

[12]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[13]  J. Bentham,et al.  Worldwide trends in children's and adolescents' body mass index, underweight and obesity, in comparison with adults, from 1975 to 2016: a pooled analysis of 2,416 population-based measurement studies with 128.9 million participants , 2017 .

[14]  Raquel S. Sevilla,et al.  Exome-wide association study of plasma lipids in >300,000 individuals , 2017, Nature Genetics.

[15]  Vincent Wai-Sun Wong,et al.  New trends on obesity and NAFLD in Asia. , 2017, Journal of hepatology.

[16]  Hae-Young Lee,et al.  Initial Report of the Korean Organ Transplant Registry (KOTRY): Heart Transplantation , 2017, Korean circulation journal.

[17]  Joshua A. Salomon,et al.  Health Effects of Overweight and Obesity in 195 Countries over 25 Years. , 2017, The New England journal of medicine.

[18]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[19]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[20]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[21]  W. Yeo,et al.  Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance , 2017, British Journal of Cancer.

[22]  G. Marchesini,et al.  When the journey from obesity to cirrhosis takes an early start. , 2016, Journal of hepatology.

[23]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[24]  Tran Quoc Bao,et al.  Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants , 2016, The Lancet.

[25]  Y. Khang,et al.  Trends in Measures of Childhood Obesity in Korea From 1998 to 2012 , 2015, Journal of epidemiology.

[26]  L. Henry,et al.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 , 2015, Hepatology.

[27]  L. Henry,et al.  Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease , 2015, PharmacoEconomics.

[28]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[29]  Chee‐Kiat Tan,et al.  Epidemiology and Clinical Evolution of Liver Cirrhosis in Singapore. , 2015, Annals of the Academy of Medicine, Singapore.

[30]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[31]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  M. Yuen,et al.  High prevalence of non‐alcoholic fatty liver disease in the Chinese – results from the Hong Kong liver health census , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[33]  Tien Yin Wong,et al.  Forecasting the burden of type 2 diabetes in Singapore using a demographic epidemiological model of Singapore , 2014, BMJ Open Diabetes Research and Care.

[34]  S. Park.  KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease , 2013, Clinical and molecular hepatology.

[35]  R. Sinha,et al.  Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium , 2013, BMJ.

[36]  K. Goh,et al.  Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia , 2013, Hepatology International.

[37]  H. El‐Serag,et al.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  Y. Kim,et al.  Relative Etiological Role of Prior Hepatitis B Virus Infection and Nonalcoholic Fatty Liver Disease in the Development of Non-B Non-C Hepatocellular Carcinoma in a Hepatitis B-Endemic Area , 2011, Digestion.

[39]  Vincent Wai-Sun Wong,et al.  Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography , 2011, Gut.

[40]  S. Caldwell,et al.  The Natural History of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[41]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[42]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[43]  Ho-Young Son,et al.  Epidemic obesity and type 2 diabetes in Asia , 2006, The Lancet.

[44]  Robert A Fisher,et al.  Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C , 2006, Hepatology.

[45]  O. Reichard,et al.  Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden , 2006, Scandinavian journal of infectious diseases.

[46]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[47]  Paul Zimmet,et al.  Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. , 2004, Diabetes care.

[48]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.

[49]  K. Tokunaga,et al.  The origin of Minnan and Hakka, the so-called "Taiwanese", inferred by HLA study. , 2001, Tissue antigens.

[50]  P. Deurenberg,et al.  Body mass index and percent body fat: a meta analysis among different ethnic groups , 1998, International Journal of Obesity.

[51]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[52]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[53]  V. Wong,et al.  Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. , 2015, Journal of hepatology.

[54]  F. Yao.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels : a role for insulin resistance and diabetes , 2008 .

[55]  N. P. Napalkov,et al.  for the prevention and control of noncommunicable diseases , 1999 .